Zoungrana-Yameogo Wedminère Noélie, Yabre Dominique Hélène Laurel, Bakiono Fidèle, Compaore Toussaint, Belem Arielle Rita, Kangoye David, Yonli Christian Philippe, Coulibaly Ouo Mireille, Drabo Koiné Maxime
Département de santé publique, Centre hospitalier universitaire de Tengandogo, Ouagadougou, Burkina Faso.
Institut de formation de la recherche interdisciplinaire en science de la santé et de l'éducation.
Med Trop Sante Int. 2025 May 12;5(2). doi: 10.48327/mtsi.v5i2.2025.643. eCollection 2025 Jun 30.
INTRODUCTION: Since the introduction of antiretroviral therapy for HIV in Burkina Faso, several treatment adherence support mechanisms have been implemented to improve outcomes and prevent resistance. Our study aimed to evaluate the knowledge and perceptions of people living with HIV (PLHIV) regarding these mechanisms in the Plateau-Central region. METHODS: We conducted a descriptive study in the Plateau-Central region, which is one of the 13 regions of Burkina Faso. PLHIV were selected as they arrived for their follow-up visits. Information was collected through interviews using a standardized questionnaire. Adherence was calculated based on the participants' reports. Those who took all their medications in the month prior to the survey were considered adherent. Quantitative variables were calculated using the averages, and qualitative variables were calculated using proportions. RESULTS: A total of 347 PLHIV were included in the study. Of these, 69% were women, with a mean age of 45.6 ± 12.2 years. The mean treatment follow-up duration was 8.6 ± 5 years. Eighty percent of individuals adhered to treatment (95% CI [75-84]). Nearly all PLHIV (99.7%) were aware of adherence support mechanisms. The most well-known mechanisms were six-month antiretroviral drug supplies (RAVI6M) (71%), discussion groups (69.9%), individual discussion (69.9%), and counseling (64.2%).The recently introduced community-based antiretroviral drug refilling program outside of health facilities was less well known (42.2%). The most commonly used measures were face-to-face discussion (64%), counseling (62%), and RAVI6M (61.7%). The most appreciated measures were the six-month supply of antiretroviral drugs (44.6%), drug counting (10.7%), and patient interview (10.1%). CONCLUSION: PLHIV are familiar with and appreciate adherence support measures. The most appreciated measure is six-monthly refills of ARV drugs. Community-based ARV supply policies should be encouraged.
引言:自布基纳法索引入抗逆转录病毒疗法治疗艾滋病毒以来,已实施了多种治疗依从性支持机制,以改善治疗效果并预防耐药性。我们的研究旨在评估中部高原地区艾滋病毒感染者(PLHIV)对这些机制的了解和看法。 方法:我们在布基纳法索13个地区之一的中部高原地区进行了一项描述性研究。PLHIV在前来进行随访时被纳入研究。通过使用标准化问卷进行访谈收集信息。依从性根据参与者的报告计算。在调查前一个月服用了所有药物的人被视为依从者。定量变量使用平均值计算,定性变量使用比例计算。 结果:共有347名PLHIV纳入研究。其中,69%为女性,平均年龄为45.6±12.2岁。平均治疗随访时间为8.6±5年。80%的个体坚持治疗(95%置信区间[75 - 84])。几乎所有PLHIV(99.7%)都知晓依从性支持机制。最知名的机制是六个月抗逆转录病毒药物供应(RAVI6M)(71%)、讨论组(69.9%)、个体讨论(69.9%)和咨询(64.2%)。最近在医疗机构外推出的基于社区的抗逆转录病毒药物补充计划知名度较低(42.2%)。最常用的措施是面对面讨论(64%)、咨询(62%)和RAVI6M(61.7%)。最受赞赏的措施是六个月抗逆转录病毒药物供应(44.6%)、药物计数(10.7%)和患者访谈(10.1%)。 结论:PLHIV熟悉并赞赏依从性支持措施。最受赞赏的措施是每六个月补充抗逆转录病毒药物。应鼓励基于社区的抗逆转录病毒药物供应政策。
Cochrane Database Syst Rev. 2010-3-17
Cochrane Database Syst Rev. 2007-1-24
Cochrane Database Syst Rev. 2008-7-16
Cochrane Database Syst Rev. 2015-2-18
Psychopharmacol Bull. 2024-7-8
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2007-1-24
Cochrane Database Syst Rev. 2025-6-11
Sante Publique. 2020
Trop Med Int Health. 2014-8